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1  |  INTRODUC TION
Intramyocellular lipid (IMCL) tends to be greater in older individu-
als, particularly in subsarcolemmal (SSL) regions (Chee et al., 2016; 
Crane et al., 2010), and has been strongly associated with insulin 
resistance (Chee et al., 2016; Li et al., 2014; Nielsen et al., 2010; 
Pan et al., 1997; Perseghin et al., 1999; Petersen et al., 2003). Why 
IMCL accumulates with increasing age is not clear, but several 
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Abstract
Intramyocellular lipid (IMCL) utilization is impaired in older individuals, and IMCL ac-
cumulation is associated with insulin resistance. We hypothesized that increasing 
muscle	total	carnitine	content	 in	older	men	would	 increase	fat	oxidation	and	 IMCL	
utilization	during	exercise,	and	improve	insulin	sensitivity.	Fourteen	healthy	older	men	
(69	±	1	year,	BMI	26.5	±	0.8	kg/m2)	performed	1	h	of	cycling	at	50%	VO2max	and,	on	a	
separate occasion, underwent a 60 mU/m2/min euglycaemic hyperinsulinaemic clamp 
before and after 25 weeks of daily ingestion of a 220 ml insulinogenic beverage (44.4 g 




a 20% increase in muscle total carnitine content (20.1 ± 1.2 to 23.9 ± 1.7 mmol/kg/dm; 
p	<	0.01)	and	a	20%	increase	in	total	fat	oxidation	(181.1	±	15.0	to	220.4	±	19.6	J/kg	
lbm/min; p < 0.01), predominantly due to increased IMCL utilization. These changes 
were	 associated	 with	 increased	 expression	 of	 genes	 involved	 in	 fat	 metabolism	
(ACAT1,	DGKD	&	PLIN2;	p < 0.05). There was no change in resting insulin-stimulated 
whole-body or skeletal muscle glucose disposal after supplementation. This is the first 
study	to	demonstrate	that	a	carnitine-mediated	increase	in	fat	oxidation	is	achievable	
in older individuals. This warrants further investigation given reduced lipid turnover is 
associated with poor metabolic health in older adults.
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studies	 have	 demonstrated	 reduced	 free	 fatty	 acid	 oxidation	 in	
older individuals, perhaps due to reduced mitochondrial function 
(Petersen et al., 2003), despite increased whole-body lipolysis and 
fatty	 acid	 availability	 compared	 to	 young	 at	 rest	 and	 during	 ex-
ercise	 (Sial	 et	 al.,	 1996;	 Solomon	 et	 al.,	 2008).	 Indeed,	 using	 an	
intravenous [U-13C]palmitate infusion approach, we (Chee et al., 
2016)	and	others	(Boon	et	al.,	2007)	have	demonstrated	that	the	
elevated rate of appearance of plasma fatty acids in response to 
exercise	at	50%	maximal	oxygen	consumption	(VO2max)	is	associ-
ated with a reduction in the relative contribution of IMCL to total 
fat	oxidation	 in	older	 individuals.	However,	 a	novel	 finding	 from	
this work (Chee et al., 2016) was that lean older men, who had 
comparable whole-body and skeletal muscle insulin sensitivity and 
SSL	IMCL	content	to	lean	young	men,	were	able	to	oxidize	a	larger	
proportion	of	 the	excess	plasma-free	 fatty	acids	during	exercise	
compared to overweight older men, in whom SSL lipid content 
increased	 during	 exercise.	 Indeed,	 lean	 older	men	 had	 a	 greater	
mRNA	expression	(Chee	et	al.,	2016)	and	maximal	activity	(Coggan	
et	al.,	1985)	of	β-hydroxyacyl-CoA	dehydrogenase,	an	 intramito-
chondrial enzyme that catalyses a rate-limiting step in β-oxidation,	
than younger counterparts of similar habitual physical activity lev-
els.	Moreover,	exercise	training	has	been	shown	to	improve	basal	
fat	oxidation	and	prevent	IMCL	accumulation	in	older	individuals	
(Sial	 et	 al.,	 1996;	 Solomon	 et	 al.,	 2008),	 and	 an	 improvement	 in	
insulin sensitivity has been previously observed with reduced SSL 
IMCL	following	several	months	of	exercise	training	where	the	ca-
pacity	to	oxidize	fatty	acids	was	increased	(Li	et	al.,	2014;	Nielsen	
et al., 2010). Thus, it would appear that a relatively high rate of 
mitochondrial	 fatty	 acid	 flux	 is	 integral	 to	 preventing	 the	 IMCL	
accumulation and insulin resistance often associated with age, but 
this	has	not	been	tested	experimentally.
Free	carnitine	plays	an	essential	role	in	regulating	fatty	acid	flux	
by facilitating the translocation of long-chain fatty acids into mito-
chondria for subsequent β-oxidation	 via	 the	 rate-limiting	 carnitine	
palmitoyltransferase	1	 (CPT1)	 reaction	 (Fritz	&	McEwen,	1959).	We	
have previously demonstrated that twice daily ingestion of 1.36 g 
L-carnitine	in	combination	with	a	beverage	containing	80	g	of	carbohy-
drate (in order to stimulate insulin-mediated muscle carnitine accumu-
lation) for up to 24 weeks can increase skeletal muscle total carnitine 







2011). Moreover, this manipulation of skeletal muscle fuel metabo-
lism prevented the increase in body fat mass associated with daily in-
gestion of a high carbohydrate beverage, and resulted in an adaptive 
increase	in	the	expression	of	gene	networks	involved	in	insulin	signal-
ling,	peroxisome	proliferator-activated	receptor	(PPAR)	signalling,	and	
fatty acid metabolism (Stephens et al., 2013). Thus, it would appear 
that muscle-free carnitine availability is limiting to the CPT1 reaction 
and	the	rate	of	fatty	acid	oxidation	in vivo at moderate, as well as high 
exercise	intensities	(van	Loon	et	al.,	2001;	Petrick	&	Holloway,	2019).	
Accordingly,	increasing	muscle	carnitine	content	is	an	ideal	approach	
to	 further	 investigate	 the	 role	 of	mitochondrial	 fatty	 acid	 flux	 and	
IMCL turnover in older individuals. Therefore, the aim of the present 
study was to test the hypothesis that a dietary mediated increase in 
skeletal muscle carnitine content would increase the rate of plasma 
fatty	acid	oxidation	during	moderate-intensity	exercise	in	older	male	
participants. We also aimed to assess whether any effect would be of 




2.1  |  Ethical approval and exercise testing
Based	on	an	anticipated	20	±	15%	 increase	 in	 total	 fatty	acid	oxi-
dation following 24 weeks of skeletal muscle carnitine loading (we 
have	previously	observed	a	10%	increase	in	fat	oxidation	following	
12 weeks, Stephens et al., 2013), an alpha of 0.05, and a power of 
0.80,	we	required	20	participants	to	be	recruited	to	allow	for	a	20%	
drop out rate. Twenty participants were recruited but 6 dropped out 
at various stages for personal reasons or problems with data col-
lection. We did not perform intention to treat analysis. Thus, 14 
healthy, non-smoking, male volunteers (age 69.1 ± 0.6 years; body 
mass	 index	(BMI)	26.5	±	0.8	kg/m2) were included in data analysis 
for the present study. The study was approved by the University of 
Nottingham's Medical School Ethics Committee in accordance with 
the	Declaration	of	Helsinki.	Written	informed	consent	was	obtained	
from all participants before taking part in the study, and they were 
made	aware	that	they	were	free	to	withdraw	at	any	point.	All	volun-
teers underwent routine medical screening and completed a general 
health questionnaire indicating their habitual frequency of perform-
ing	physical	activities	including	resistance	exercise,	running,	cycling	
and	 swimming.	 Exclusion	 criteria	 included	 evidence	 of	 metabolic	
disease, cardiovascular disease, overt muscle wasting, cerebrovas-
cular disease, respiratory disease, inflammatory bowel disease, renal 
disease or a clotting dysfunction. Participants prescribed statins, 
aspirin	 or	 NSAID’s	 were	 instructed	 to	 continue	medication.	 On	 a	
separate visit, all participants performed a continuous incremen-
tal	 exhaustive	 exercise	 test	 on	 an	 electronic-braked	 cycle	 ergom-
eter	(Excalibur,	Lode,	The	Netherlands)	to	determine	their	maximal	
rate	of	oxygen	consumption	(VO2max;	Quark	CPET,	Cosmed,	Italy).	
To	calculate	 the	workload	 that	would	elicit	50%	VO2max,	 the	 test	
started at a workload of 1 W/kg body mass and involved four 3 min 
stages of 20 to 30 W increments, followed by several 1 min stages 
of	20	 to	30	W	 increments	 to	exhaustion	 in	order	 to	minimize	 the	
duration	of	strenuous	exercise	and	the	risk	of	adverse	cardiovascular	
events. Heart rate was measured throughout. The workload corre-
sponding	to	50	±	2.5%	VO2max	was	confirmed	 in	a	 familiarization	
visit at least 3 days later.
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2.2  |  Experimental protocol
Subjects	reported	to	the	David	Greenfield	Human	Physiology	Unit	
at the University of Nottingham Medical School on three occasions. 
On	the	first	occasion,	they	completed	a	quality	of	life	(SF-36)	ques-
tionnaire and performed an incremental shuttle walking test (ISWT). 
Briefly,	 the	 test	 required	 the	patients	 to	walk	 up	 and	down	a	10-
metre course, set out in a quiet corridor of the Unit, at a gradually 
increasing speed, paced by audio signals (bleeps), until they were 




structive pulmonary disease patients in order to provide objective 
measurement of disability, but has also been used to assess func-
tional	exercise	capacity	in	older	individuals	(Harrison	et	al.,	2013).
On	the	second	visit	(Resting visit), they arrived at the unit at ap-
proximately	0800	after	an	overnight	fast,	having	abstained	from	ex-
ercise	and	alcohol	for	the	previous	48	h.	On	arrival,	lean	soft	tissue	
mass (kg), fat mass (kg) and bone mineral content (kg) of standard 
body	regions	were	measured	using	dual-energy	X-ray	absorptiom-
etry	 (DXA;	 Lunar	 Prodigy,	 GE	 Healthcare,	 US).	 Participants	 were	
then asked to rest in a supine position on a bed while cannulae were 
inserted into a vein on the dorsal surface of the hand for arterial-
ized-venous	blood	sampling	(Gallen	&	MacDonald,	1990),	the	fore-
arm	 for	 the	 infusion	of	 insulin	 (Actrapid;	Novo	Nordisk,	Denmark)	
and	 20%	 dextrose	 (Baxter	 Healthcare,	 UK),	 and	 the	 contralateral	
forearm	for	the	infusion	of	2-deoxy-D-glucose	(2DG;	Sigma-Aldrich,	
UK). Thereafter, a 3 h euglycaemic (4.5 mmol/l) hyperinsulinaemic 
(60 mU/m2/min) clamp was commenced in combination with the in-
travenous	 infusion	of	2DG	 (6	mg/kg/h)	 to	assess	whole-body	and	
skeletal muscle insulin sensitivity, respectively, as described pre-
viously	 (Chee	 et	 al.,	 2016).	 VO2	 and	VCO2 were measured over a 
20 min period of quiet rest via a ventilated hood connected to an 
indirect	calorimeter	 (GEMNutrition	Ltd,	UK)	prior	 to	and	after	2	h	
of	 the	clamp.	Arterialized-venous	blood	was	obtained	every	5	min	
for immediate measurement of blood glucose concentrations (Stat 
Analyzer,	YSI	Inc,	USA),	and	every	30	min	for	subsequent	analysis	of	
serum	insulin	and	plasma	2DG.	 In	addition,	needle	biopsy	samples	
were	 obtained	 from	 the	 vastus	 lateralis	 (Bergstrom,	 1979)	 before	
and immediately after the clamp and snap frozen in liquid nitrogen. 
After	3	h,	the	insulin	and	2DG	infusions	were	stopped,	whereas	the	
dextrose	infusion	was	continued	for	approximately	80	min	and	the	
subjects were fed a high carbohydrate meal in order to stabilize 
blood glucose concentration. Thereafter, participants were free to 
leave the laboratory.
On	the	third	visit	(Exercise visit), at least 1 week later, volunteers 
again	reported	to	the	Unit	at	approximately	0800	following	an	over-
night fast and rested semi-supine on a bed while cannulae were 
inserted into a heated hand vein for arterialized-venous blood sam-
pling and a forearm vein for the infusion of NaH13CO3 (Cambridge 
Isotope	 Laboratories,	 USA)	 and	 [U-13C]palmitate (99% enriched; 
Cambridge	Isotope	Laboratories,	USA)	bound	to	4.5%	human	serum	
albumin	(Zenalb	4.5,	Bio	Products	Laboratory	Limited,	UK)	at	a	ratio	
of	 approximately	 3:1	 (1.94:0.64	 μmol/L). Following a 63.75 μg/kg 
bolus of NaH13CO3 to prime the bicarbonate pool, [U-
13C]palmitate 







analysis of fatty acids and catecholamines, respectively, were stored 
at	−80°C.	Breath	samples	were	also	collected	every	10	min	during	
exercise	via	one-way	valve	bags	and	introduced	into	vacuumed	glass	
tubes	 (Exetainer,	 Labco	Ltd,	UK)	 for	 subsequent13CO2 enrichment 
analysis.	 During	 the	 last	 10	min	 of	 exercise,	 when	 the13CO2 pro-
duction was at a steady-state, indirect calorimetry was performed 
(Quark	CPET	system,	Cosmed,	 Italy).	 In	addition,	a	vastus	 lateralis	
needle	 biopsy	was	obtained	 immediately	 before	 and	 after	 the	 ex-
ercise bout and processed within 10 s to minimize ex vivo changes 
in intracellular metabolism and contamination of the IMCL pool by 
extracellular	adipocytes.	A	5	mg	portion	was	buffered	in	ice-cold	3%	
gluteraldehyde/0.1 M sodium cacodylate (pH 7.4) and stored at 4◦C 
for subsequent electron microscopy processing, and the remainder 
immediately	frozen	in	liquid	nitrogen.	After	the	exercise	bout	the	[U-
13C]palmitate infusion was stopped, participants were fed lunch, and 
they were free to leave the laboratory.
Following the Exercise	experimental	visit,	the	participants	were	
randomized in a double-blind fashion to receive 4.5 g of either 
maltodextrin	placebo	 (Control)	or	L-carnitine	L-tartrate	 (Carnitine),	
which	equated	 to	3	g	of	 L-carnitine	 (Carnipure;	 Lonza	Group	Ltd.,	
Basel,	Switzerland),	once	a	day	for	25	weeks.	The	participants	were	
instructed to ingest the supplement with a 220 ml insulinogenic 
beverage	containing	44.4	g	of	carbohydrate	and	13.8	g	of	protein	
(Ensure	Plus,	Abbott	Nutrition,	USA)	between	breakfast	and	lunch	
instead of their usual mid-morning snack. We used this alternative 
insulinogenic beverage because our previously used protocol of 
twice	daily	feeding	of	80	g	of	carbohydrate	could	be	detrimental	to	
metabolic	health	and	liver	function	in	older	individuals.	During	this	
25-week dietary intervention, period participants attended the Unit 
twice	 a	week	 to	 undergo	1	 h	 of	 supervised	 exercise	 on	 the	 cycle	
ergometer	at	their	pre-determined	50%	VO2max	in	order	to	increase	
demand	for	fat	oxidation	and	enhance	any	effect	of	increasing	mus-
cle carnitine content. The sessions were limited to twice a week and 
exercise	workload	 did	 not	 change	 over	 the	 intervention	 period	 in	
order to make the intervention more easily translatable to every-day 
life	and	to	avoid	any	excessive	training	effect,	which	is	also	known	
to	 improve	fat	oxidation,	 IMCL	content	and	 insulin	sensitivity.	The	
Resting and Exercise	 experimental	 visits	 were	 then	 repeated	 after	
24 and 25 weeks, respectively, with the shuttle walk test and SF36 
questionnaire performed again a few days after the cessation of 
supplementation.
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2.3  |  Sample analysis





of	2-deoxy-D-glucose-6-phosphate	 (2DG6P)	 content	using	a	 com-
mercial	spectrophotometric	kit	method	(Cosmo	Bio	Ltd,	Japan;	Saito	
et	 al.,	 2011).	 In	 addition,	 total	 RNA	 was	 extracted	 from	 approxi-
mately 20 mg of wet muscle tissue (Trizol reagent; Invitrogen Ltd, 
UK)	and	following	generation	of	 first-strand	cDNA	 (SuperScript	 III	
kit;	Invitrogen	Ltd,	UK),	the	relative	abundance	of	mRNA	of	12	genes	
from	pathways	involved	in	FFA	oxidation	and	IMCL	metabolism	was	
determined using custom-designed low-density RT-PCR array mi-
crofluidic	cards	(Applied	Biosystems,	Foster	City,	CA,	USA)	in	com-
bination	with	 the	 ABI	 PRISM	 7900	 T	 sequence	 detection	 system	
and	SDS	2.1	 software	 (Applied	Biosystems,	Foster	City,	CA,	USA;	
Stephens et al., 2013). The threshold cycle CT was automatically 
given	by	the	SDS	software	RQ	manager,	and	relative	mRNA	abun-
dance was calculated using the ΔΔCT	method	with	 each	 subjects’	
baseline sample (0 week) as their own calibrator and α-actin as the 
endogenous control. CT values for α-actin did not change across time 
points (data not shown).
Plasma from the Exercise	 experimental	 visits	was	 analysed	 for	
total	 fatty	 acids	 (NEFA	 C	 kit,	WAKO	 Chemicals,	 Germany)	 on	 an	
automated	analyzer	(ABX	Pentra	400,	Horiba	Medical	Ltd.,	France),	
and [U-13C]palmitate	 and	 palmitate	 by	 TSQ	 triple	 quadrupole	 gas	
chromatography–mass	 spectrometry/mass	 spectrometry	 (GC-MS/
MS,	 Thermo,	 UK)	 and	 GC-MS	 (MD800,	 Fisons,	 UK)	 respectively,	
after addition of a heptadecanoic internal standard and derivat-
ization	 to	 their	 methyl	 esters	 (Husek	 et	 al.,	 2002).	 Breath13CO2 
enrichment was analysed by continuous-flow isotope-ratio MS 
(CF-IRMS;	 AP2003	 Breath	 Gas	 System,	 Analytical	 Precision,	 UK;	
Scrimgeour	 et	 al.,	 1988).	 High-performance	 liquid-chromatogra-
phy (HPLC) with electrochemical detection was used to measure 
plasma	adrenaline	and	noradrenaline	concentrations	(MacDonald	&	
Lake,	1985).	Muscle	samples	 for	 transmission	electron	microscopy	
were	 fixed	 in	1%	osmium	 tetroxide,	dehydrated	 in	graded	ethanol	
series and embedded in two resin blocks. Three ultrathin 70–90 
nanometre sections were cut from each block, mounted on cop-
per grids, and stained in uranyl acetate and lead acetate, with one 
section randomly selected to be visualized at ×4200 magnification. 
Approximately	40	 fields	of	 view	 from	up	 to	40	 longitudinal	 fibres	
were systematically randomly selected by a blinded operator using 
the corners of copper grid squares as a guide. This method obtained 
at least 6 images per sample containing a SSL region, which was re-
quired	for	reproducible	estimation	of	IMCL	droplet	(LD)	character-
istics. Images were analysed using Image J to determine percentage 
of	 intermyofibrillar	 (IMF)	and	SSL	area	covered	by	LD,	LD	size	and	
total	number	of	LD	per	square	micrometre	of	local	tissue	area,	which	
have been previously shown (Crane et al., 2010) to produce values 
similar	to	3D	stereology	volume	estimates	(Howald	et	al.,	1985).	In	
addition, a 50 mg portion muscle was freeze-dried, dissected free 
of visible blood and connective tissue, pulverized and used for the 
quantification of free-, acetyl- and long-chain acylcarnitine content 
(Cederblad et al., 1990; Stephens et al., 2006), as well as glycogen, 
lactate and phosphocreatine (PCr) as previously described (Harris 
et al., 1974). Total carnitine content was calculated from the sum of 
free and acylcarnitine moieties.
2.4  |  Calculations and statistical analysis
A	 single	 operator	 analysed	 all	 DXA	 scans	 to	 determine	 leg,	 arm,	
and trunk composition using the standardized regions specified by 
the	manufacturer	(enCORE	2005	version	9.1,	GE	Medical	Systems,	
Bucks,	 U.K.).	 Homeostatic	model	 assessment	 of	 insulin	 resistance	
(HOMA-IR)	was	calculated	by	the	equation	of	Matthews	et	al.	(1985)	
using	 fasting	 glucose	 (G;	mmol/L)	 and	 insulin	 (I;	mU/L)	 concentra-
tions	((G	×	I)/22.5).	 Insulin	sensitivity	 index	(SIClamp) was calculated 
using	the	equation	of	Matsuda	and	DeFronzo	(SIClamp	=	M/(G	×	ΔI); 
Matsuda	 &	 DeFronzo,	 1999)	 where	 steady-state	 (120–180	 min)	
glucose disposal (M) is normalized for steady-state blood glucose 
concentration	(G;	mmol/L)	and	the	difference	between	fasting	and	






(862	g/mol)	 liberates	39.4	kJ	and	1	g	of	glucose	 (180	g/mol)	 liber-
ates 15.6 kJ. The rate of appearance (Ra), disappearance (Rd), and 
oxidation	of	palmitate	during	the	final	10	min	of	exercise	were	used	
to calculate total plasma fatty acid kinetics by dividing the fractional 
contribution of plasma palmitate to total plasma fatty acid concen-
tration as previously described (Chee et al., 2016; van Loon et al., 
2001). The contribution of other fat sources was calculated by sub-
tracting	plasma	fatty	acid	oxidation	from	total	 fat	oxidation	calcu-
lated via indirect calorimetry.
Differences	within	and	between	groups	before	and	after	supple-
mentation (time and treatment effects) were analysed using a two-
way	ANOVA,	and	differences	within	and	between	groups	pre-	and	
post-exercise	 or	 euglycaemic	 hyperinsulinaemic	 clamp	 before	 and	




post hoc test was performed to identify individual differences. 
When	a	significant	 interaction	effect	 (time	×	 treatment	×	exercise	
or	 insulin)	was	 observed	 following	 three-way	ANOVA,	 a	 two-way	
ANOVA	with	Sidak's	post	hoc	test	was	performed	on	the	post-sup-
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discussed. Statistical significance was set at p < 0.05, and all values 
are	presented	as	means	±	SD.
3  |  RESULTS
3.1  |  Subject characteristics
Subject	 characteristics	 are	 presented	 in	 Table	 1.	 Age,	 statin	 use,	
body	 composition,	 VO2max,	 functional	 capacity	 as	 measured	 by	
ISWT, and quality of life score as measured by SF36 questionnaire 
were similar between Control and Carnitine groups at baseline and 
following 25 weeks of supplementation. There was a time × treat-
ment interaction for fasting blood glucose (p = 0.0455) and a trend 
for fasting blood glucose to be around 6% lower in Carnitine after 
25 weeks (p = 0.0957). However, there was no time × treatment in-
teraction for serum insulin concentration (p = 0.2345), and, as such, 
HOMA	 IR	was	 not	 different	 between	 Carnitine	 and	 Control	 over	
time (time × treatment interaction p = 0.1431).
3.2  |  Skeletal muscle total carnitine content
There	was	a	time	x	treatment	 interaction	for	skeletal	muscle	total	
carnitine content (p < 0.05). Twenty-five weeks of supplementation 
had no effect on skeletal muscle total carnitine content in Control 
(16.7 ± 3.9 to 17.2 ± 4.0 mmol/kg dry muscle (dm); Figure 1a). In 
contrast, from a similar baseline value to Control, skeletal mus-
cle total carnitine content increased by around 20% in Carnitine 
after 25 weeks (20.3 ± 3.4 to 24.2 ± 3.7 mmol/kg dm; p < 0.001; 
Figure 1a), such that it was also greater than Control (p < 0.01; 
Figure	1a).	There	was	no	effect	of	exercise	on	skeletal	muscle	total	
carnitine content in either group over the twenty-five weeks of 
carnitine	supplementation	(time	×	treatment	×	exercise	interaction	
p = 0.5431; Figure 1b).
3.3  |  Whole-body and skeletal muscle metabolism 
during exercise
Total	 energy	 expenditure	 (459.7	 ±	 39.5	 to	 465.4	 ±	 56.6	 vs.	
477.7	±	71.2	to	507.8	±	36.1	J/kg	lean	body	mass	(lbm)/min,	respec-
tively)	 and	 carbohydrate	 oxidation	 (256.4	 ±	 22.7	 to	 267.3	 ±	 29.9	
vs.	 296.5	±	27.7	 to	287.4	±	27.3	 J/kg	 lbm/min,	 respectively)	were	
similar between Control and Carnitine before and after 25 weeks 
of	 supplementation	when	exercising	at	 similar	 absolute	workloads	
of	53.7	±	15.2	and	48.4	±	18.9	W,	respectively	(Figure	2a).	In	con-
trast,	there	was	a	time	×	treatment	interaction	for	total	fat	oxidation	
(p	<	0.05)	such	 that	 it	was	 increased	by	21%	during	exercise	 from	
181.1	±	53.4	to	220.4	±	67.3	J/kg	 lbm/min	 in	Carnitine	 (p < 0.01). 
However,	 there	 was	 no	 difference	 in	 fatty	 acid	 oxidation	 from	
plasma or other sources (Figure 2a), plasma fatty acid Ra (Figure 2b), 
Rd	(Figure	2c),	or	%	of	Rd	oxidized	(Figure	2c),	or	the	change	in	IMF	
or	SSL	LD	area,	size	or	number	during	exercise	between	Control	and	
Carnitine at baseline or after 25 weeks of supplementation (Table 2).
There	was	 a	 treatment	×	 exercise	 interaction	 effect	 for	 skele-
tal muscle PCr content (p < 0.01; Figure 3a) and a main effect of 
exercise	 for	skeletal	muscle	glycogen	 (p < 0.01; Figure 3b), lactate 
Control Carnitine
0 weeks 25 weeks 0 weeks 25 weeks
Age	(years) 68	±	3 69 ± 3*** 70 ± 2 70 ± 2***
Statin use (n) 3 3 3 3
Body	mass	(kg) 77.5 ± 10.4 79.9 ± 7.3 78.5	±	10.4 78.0	±	9.4
BMI	(kg/m2) 25.7 ± 3.2 26.5 ± 2.6 27.2 ± 3.1 27.1 ± 3.1




4.7 ± 0.3 4.8	±	0.6 5.0 ± 0.3 4.7 ± 0.4
Fasting serum 
insulin (mU/L)
10.6 ± 4.2 12.0 ± 7.9 9.5 ± 5.0 7.9 ± 4.1
HOMA	IR 2.2 ± 0.9 2.7 ± 1.9 2.2 ± 1.2 1.7 ± 1.0
VO2max	(ml/kg/
lbm/min)
41.2 ± 5.0 ND 41.9 ± 5.0 ND
ISWT (metres) 558.6	±	96.0 555.7	±	89.6 562.9 ± 73.9 588.6	±	47.4
SF36v2™score (%) 89.0	±	9.4 89.6	±	9.5 86.0	±	9.0 87.7	±	7.6
All	values	(n	=	7)	are	means	±	standard	deviation	(SD).
ND,	not	determined.
***p < 0.001, 25 weeks significantly greater than 0 weeks. 
**p < 0.05, significant time × treatment interaction. 
TA B L E  1 Subject	characteristics
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(p < 0.01; Figure 3c), carnitine (p < 0.0001; Figure 1b) and acetyl-
carnitine (p < 0.0001; Figure 1b). Thus, whereas PCr appeared to be 
reduced	during	exercise	to	a	lesser	degree	in	Carnitine	compared	to	
control before and after 25 weeks of supplementation, there was 
no difference between groups in the reduction in muscle glycogen 
and carnitine, and the reciprocal increases in muscle lactate and 
acetylcarnitine,	following	exercise.	There	was	around	a	0.7	mmol/l	
lower	 steady-state	 blood	 lactate	 concentration	 during	 exercise	 in	
both Control and Carnitine following 25 weeks of supplementation 
(Figure 3b; p	 <	 0.01,	 time	 x	 exercise	 interaction).	 However,	 there	
were no differences between groups in the increase in plasma fatty 




F I G U R E  1 Average	skeletal	muscle	total	carnitine	content	
(a), and the contribution of free carnitine (filled bars) and 
acetylcarnitine (open bars) to skeletal muscle carnitine content 
before	(Pre)	and	after	(Post)	1	h	of	exercise	at	50%	VO2max	(b),	
before (0 weeks) and after 25 weeks of daily supplementation 
with 4.5 g of placebo (Control) or L-carnitine L-tartrate (Carnitine) 
in combination with 220 ml of a nutritional beverage containing 
13.8	g	protein	and	44.4	g	carbohydrate.	Values	represent	mean	
±SEM (n = 7). **p < 0.01, ***p < 0.001, total carnitine at 25 weeks 
in Carnitine significantly different to corresponding 0 weeks 
value. +p < 0.05, ++p < 0.01, total carnitine at 25 weeks in Carnitine 
significantly different to corresponding Control value. Individual 
responses for average total muscle carnitine content (a) are 
represented by filled circles and connected with lines






25 weeks of daily supplementation with 4.5 g of placebo (Control) 
or L-carnitine L-tartrate (Carnitine) in combination with 220 ml 
of	a	nutritional	beverage	containing	13.8	g	protein	and	44.4	g	
carbohydrate. Values represent mean ±SEM (n = 7). **p < 0.01, 
total	fat	oxidation	at	25	weeks	in	Carnitine	significantly	different	to	
corresponding 0 weeks value. Individual responses for total energy 
expenditure	(a),	plasma	FFA	Ra	(b)	and	Rd	(c)	are	represented	by	
filled circles and connected with lines
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3.4  |  Insulin sensitivity and body composition
The steady-state rate of glucose disposal during the final hour 
of the 3-h euglycaemic hyperinsulinaemic clamp was similar 











































































































































































































































































































































































































































































































































































































































































F I G U R E  3 Skeletal	muscle	PCr	(a),	glycogen	(b),	and	lactate	(c)	
before	(Pre)	and	immediately	after	(Post)	1	h	of	exercise	at	50%	
VO2max	after	25	weeks	of	daily	supplementation	with	4.5	g	of	
placebo (Control; open bars) or L-carnitine L-tartrate (Carnitine; 
filled bars) in combination with 220 ml of a nutritional beverage 
containing	13.8	g	protein	and	44.4	g	carbohydrate.	Values	
represent mean ± SEM (n = 7). ††p	<	0.01,	treatment	×	exercise	
effect,	PCr	increase	during	exercise	significantly	greater	than	
corresponding Control
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measurably	 after	 24	 weeks	 (48.3	 ±	 12.9	 to	 46.6	 ±	 17.1	 vs.	
51.2	±	19.8	to	48.9	±	15.5	μmol/kg lbm/min, respectively). Steady-
state serum insulin concentration was also similar between Control 
and	Carnitine	at	0	and	24	weeks	(125.5	±	18.0	to	134.6	±	19.8	vs.	
131.5	±	17.6	to	127.7	±	20.8	mIU/L,	respectively).	As	such,	 there	
was no effect on ISclamp between groups (Figure 5a). There was 
also no effect of 24 weeks of supplementation on skeletal muscle 
insulin	 sensitivity	 as	measured	by	 steady-state	 plasma	2DG	 con-
centration between Control and Carnitine during the hyperinsu-
linaemic	euglycaemic	clamp	 (data	not	 shown)	and	muscle	2DG6P	
content	 (Figure	5b;	44.3	±	19.5	 to	45.5	±	28.3	vs.	45.1	±	18.5	 to	
51.0 ± 15.7 μmol/kg wm respectively). However, there was a time 
x	treatment	interaction	(p < 0.05) for RER, resulting in a lower RER 
in Carnitine before and during the hyperinsulinaemic euglycaemic 
clamp after 24 weeks (p < 0.05; Figure 5c). Whole-body fat mass 
remained similar over 24 weeks of supplementation in both Control 
and Carnitine (20.1 ± 9.5 to 22.0 ± 7.5 vs. 19.4 ± 5.7 to 19.3 ± 5.2 kg; 
Figure 5d). Indeed, there was no difference in trunk, arm, or leg fat 
mass within or between Control and Carnitine over the course of 
the study (Figure 5d).
3.5  |  Skeletal muscle gene expression
The	 fold	 change	 in	 expression	 of	 skeletal	 muscle	 transcripts	 in-
volved	 in	 fatty	 oxidation	 (ACAT1)	 and	 IMCL	 turnover	 (DGKD	 and	
PLIN2) was greater (p < 0.05) in Carnitine compared with Control at 
24 weeks (Table 3), whereas changes in other measured transcripts 
were similar between groups.
4  |  DISCUSSION
The aim of the present study was to test the hypothesis that a di-
etary mediated increase in skeletal muscle carnitine content would 
increase	 the	 rate	 oxidation	of	 plasma	 fatty	 acid	 during	moderate-
intensity	 exercise	 in	 older	 male	 participants.	 We	 also	 aimed	 to	
 assess whether any effect would be of a magnitude to reduce rest-
ing IMCL content, insulin resistance and fat mass over 25 weeks of 
moderate-intensity	exercise	prescription	in	older	 individuals.	Thus,	
the main finding from the present study was that a 20% increase 
in muscle total carnitine content resulted in around a 20% increase 
F I G U R E  4 Plasma-free	fatty	acid	(FFA;	a),	blood	lactate	(b),	and	plasma	noradrenaline	(c)	and	adrenaline	(d)	concentration	during	1	h	of	
exercise	at	50%	VO2max	before	(circles)	and	after	(squares)	25	weeks	of	daily	supplementation	with	4.5	g	of	placebo	(Control;	open	symbols)	
or	L-carnitine	L-tartrate	(Carnitine;	filled	symbols)	in	combination	with	220	ml	of	a	nutritional	beverage	containing	13.8	g	protein	and	44.4	g	
carbohydrate. Values represent mean ± SEM (n = 7)
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in	 whole-body	 total	 fatty	 acid	 oxidation	 during	 exercise	 at	 50%	
VO2max,	which	was	 likely	due	to	an	 increase	 in	 IMCL,	 rather	than	
plasma fatty acid, utilization. However, this apparent increase in 
IMCL	turnover	during	moderate-intensity	exercise	did	not	translate	
into a reduction in resting SSL IMCL content or an improvement in 
insulin sensitivity and whole-body and regional fat mass. Whether 
this	was	because	the	exercise	prescription	volume	and/or	duration	
was	not	of	sufficient	magnitude	to	translate	the	 increased	fat	oxi-
dation into a measurable change in IMCL content, requires further 
investigation, but it would appear that a carnitine-mediated increase 
in	mitochondrial	fatty	acid	flux	is	achievable	in	older	individuals.
We have previously demonstrated that twice daily ingestion of 
1.36 g L-carnitine for 12 to 24 weeks, in combination with a bev-
erage	 containing	 80	 g	 of	 carbohydrate	 in	 order	 to	 stimulate	 insu-
lin-mediated muscle carnitine accumulation, can increase skeletal 
muscle total carnitine content by around 20% in young healthy men 
(Stephens et al., 2013; Wall et al., 2011). This was in line with our pre-
vious research demonstrating that intravenously infusing L-carnitine 
in the presence of high circulating insulin (>50 mU/L) increased mus-
cle carnitine content by 15% (Stephens et al., 2006a, 2007), and that 
ingesting	>80	g	carbohydrate	 in	a	beverage	 increased	whole-body	
(Stephens et al., 2007) and forearm muscle (Shannon et al., 2016) 
carnitine retention when combined with 3 g of L-carnitine feeding. 
A	novel	 finding	 of	 the	 present	 study	was	 that	 combining	 3	 g/day	
supplementation of L-carnitine with a protein containing insulino-
genic	 beverage	 with	 lower	 carbohydrate	 content	 (44.4	 vs.	 80	 g),	
known to increase serum insulin concentration to around 100 mU/L 
(Dirks	 et	 al.,	 2020),	 increased	 skeletal	 muscle	 total	 carnitine	 con-
tent by around 20% in older individuals (~20 to ~24 mmol/kg dm). 
A	 recent	 study	by	Bruls	 et	 al.	 (2019)	 demonstrated	 that	 ingestion	
of 1.36 g/d L-carnitine (2 g L-carnitine L-tartrate) for just 36 days 
could	increase	muscle	total	carnitine	content	by	around	12%	(8.5–
9.5 mmol/kg dm) in 60-year-old individuals with impaired glucose 
tolerance. This increase is in line with the present findings, as well 
as previous calculations that ingestion of 3 g of L-carnitine combined 
with an insulinogenic beverage would increase the muscle store by 
F I G U R E  5 Steady-state	insulin	sensitivity	index	(a),	skeletal	muscle	2-deoxyglucose-6-phosphate	accumulation	(2DG6P;	b),	and	fasting	
and	2	h	insulin-stimulated	respiratory	exchange	ratio	(RER;	c)	during	a	3	hr	hyperinsulinaemic	(60	mU/m2/min) euglycaemic clamp, as well 
as	legs	(open	bar),	arms	(shaded	bar),	and	trunk	(filled	bar)	fat	mass	measured	by	DXA	(d),	before	(0	weeks;	open	bars,	circles)	and	after	
(24 weeks; filled bars, squares) 24 weeks of daily supplementation with 4.5 g of placebo (Control; open symbols) or L-carnitine L-tartrate 
(Carnitine;	filled	symbols)	in	combination	with	220	ml	of	a	nutritional	beverage	containing	13.8	g	protein	and	44.4	g	carbohydrate.	Values	
represent mean ± SEM (n = 7). *p < 0.05, RER at 25 weeks in Carnitine significantly different to 0 weeks. Individual responses for insulin 
sensitivity	index	(a),	muscle	2DG6P	(b)	and	total	fat	mass	(d)	are	represented	by	filled	circles	and	connected	with	lines
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0.1–0.3%/day (Shannon et al., 2016; Stephens, Evans, et al., 2007). 
The fact that an insulinogenic beverage was not used in the study of 
Bruls	et	al.	(2019)	is	difficult	to	reconcile	with	previous	findings	that	
neither daily feeding of L-carnitine per se for up 3 months (Wächter 
et al., 2002), nor intravenously infusing L-carnitine for up to 5 h 
(Stephens et al., 2006a), had an effect on muscle total carnitine con-
tent, or indeed net uptake of carnitine across the leg (Soop et al., 
1988)	 or	 forearm	 (Shannon	et	 al.,	 2016)	 in	 the	 absence	of	 insulin.	
However,	possible	explanations	could	be	 that	 the	L-carnitine	dose	
was spilt across three meals that were presumably very insulino-
genic in a cohort with impaired glucose tolerance and able to stim-
ulate muscle carnitine uptake, or that the individuals with impaired 
glucose	tolerance	were	muscle	carnitine	deficient	(8.5	mmol/kg	dm).
A	 major	 finding	 of	 the	 present	 study	 was	 that	 the	 increase	 in	
muscle carnitine content was associated with a remarkable 20% in-
crease	 in	the	rate	of	whole-body	total	 fat	oxidation	during	exercise	
at	 50%	VO2max,	 compared	with	 placebo	 group	 response	 that	was	
unchanged. The pre-supplementation values for whole-body total fat 
oxidation	during	exercise,	as	well	as	those	of	total	energy	expenditure	
and the relative contribution of plasma and other fat sources, were di-
rectly	in	line	with	previous	studies	in	older	individuals	exercising	at	the	
same	intensity	(Boon	et	al.,	2007).	The	post-supplementation	values	




reduced	 fat	 oxidation	 in	 older	 individuals	 despite	 increased	whole-




idation. However, by using an intravenous [U-13C]palmitate infusion 
approach combined with electron microscopy analysis of net IMCL 
utilization,	we	demonstrated	no	 change	 in	plasma	 fatty	 acid	oxida-
tion	with	increased	whole-body	total	fat	oxidation,	and	no	change	in	
plasma fatty acid rate of appearance (presumably from adipose tissue 
and consistent with the unaltered catecholamine concentrations), rate 
of	disappearance	(half	of	which	is	thought	to	enter	exercising	skeletal	
muscle), or the proportion of fatty acids leaving the circulation that 
are	oxidized	rather	than	stored.	On	the	other	hand,	we	did	observe	
a	time	x	exercise	interaction	effect	for	SSL	IMCL	content,	which	may	
suggest	 that	 IMCL	utilization	drove	 the	 increase	 in	 fat	 oxidation	 in	
Carnitine despite SSL IMCL content also decreasing in Control. The 
reason	 for	 a	 selective	oxidation	of	 IMCL	over	plasma	 fatty	 acids	 is	
unclear	but	 is	perhaps	due	 to	 an	exercise	 training	effect	 combined	
with	a	carnitine-mediated	increase	in	energy	expenditure,	particularly	







selective	oxidation	of	 IMCL	could	also	be	due	to	a	 local	 increase	of	
free carnitine content in the vicinity of IMF mitochondrial IMCL (i.e. 
lipid	droplets	proximal	to	mitochondria)	as	we	have	previously	spec-
ulated (van Loon et al., 2001; Stephens, Constantin-Teodosiu, et al., 
2007;	Stephens	&	Galloway,	2013),	particularly	given	 free	carnitine	
availability	increased	by	50%	during	exercise.
The premise of the present study was that a carnitine-mediated 
increase	in	total	fat	oxidation	over	25	weeks	of	moderate-intensity	
exercise	prescription	would	 lead	 to	a	 reduction	 in	 IMCL	content.	
We have previously demonstrated that only IMF, but not SSL, IMCL 
content	declines	with	exercise	in	lean	active	older	individuals,	pre-
dominantly due to a reduction in lipid droplet number, and that 
SSL	IMCL	content	increases	with	exercise	in	overweight	sedentary	
older individuals, predominantly due to increased lipid droplet size 
(Chee	et	al.,	2016).	We	observed	a	similar	pattern	before	exercise	
prescription in the present study, but an increase in IMF IMCL uti-
lization	and	a	reduction	in	SSL	IMCL	accumulation	during	exercise	
after training regardless of treatment. However, this did not result 
in a decline in IMCL content after 25 weeks of supplementation, 
even	when	total	fat	oxidation	was	increased	with	muscle	carnitine	
loading.	The	few	pertinent	exercise	training	studies	of	older	 indi-
viduals	 (~67	 y)	 demonstrated	 that	 12	weeks	 of	 exercise	 training	
(30–60	min	at	60–75%	VO2max,	4–6	times/week)	increased	basal	
fat	oxidation	(Solomon	et	al.,	2008)	and	mitochondrial	content	and	




Nielsen et al., 2010). Notably, these studies involved substantially 
greater training intensities / frequencies over a shorter period of 
TA B L E  3 Fold	change	in	expression	of	skeletal	muscle	
transcripts	encoding	proteins	involved	in	fatty	acid	oxidation	and	
IMCL turnover following 24 weeks of daily supplementation with 
4.5 g of placebo (Control) or L-carnitine L-tartrate (Carnitine) in 
combination with 220 ml of a nutritional supplement containing 
13.8	g	protein	and	44.4	g	carbohydrate
Gene Control Carnitine
Fatty	acid	oxidation ACACB 1.19 ± 0.59 1.32 ± 0.71
CPT1B 1.95 ± 2.02 1.17	±	0.58
CPT2 1.42 ± 0.61 0.99 ± 0.44
HADHB 0.80	±	0.80 1.09 ± 0.46
ACADM 0.78	±	0.43 1.08	±	0.41
ACAT1 0.82	±	0.51 1.33 ± 0.31*
IMCL turnover SPTLC1 1.17	±	0.83 1.15 ± 0.36
DGKD 0.85	±	0.11 1.23 ± 0.17+
DGAT1 0.93 ± 0.31 1.05 ± 0.16
PLIN2 0.76 ± 0.56 1.23 ± 0.23+
PLIN5 1.26	±	0.81 1.48	±	1.39
PNPLA2 1.82	±	0.93 1.25 ± 0.54
All	values	(n	=	7)	are	means	±standard	deviation	(SD).
*p < 0.05, Carnitine different to corresponding Control value. 
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time than were used in our study, which would suggest that a car-
nitine-mediated	increase	in	fat	oxidation	may	be	required	in	combi-
nation with a larger training load, or that muscle carnitine content 
should be elevated in the months before prolonged L-carnitine sup-
plementation and training commences. Indeed, we have previously 
demonstrated that carnitine supplementation in younger trained 
individuals who were partaking in regular high-intensity endurance 
exercise	increased	skeletal	gene	muscle	expression	of	the	PNPLA2,	
which encodes for adipose triglyceride lipase the rate-limiting step 
in	IMCL	hydrolysis,	and	PNPLA2	gene	expression	was	unchanged	
with	carnitine	 loading	 in	the	present	study.	Nevertheless,	the	ex-
pression of other genes involved in IMCL turnover, PLIN2 (perilipin 
2),	and	lipid	intermediate	metabolism,	DGKD	(diacylglycerol	kinase	
delta), was increased with carnitine supplementation, and it is gen-
erally accepted that the accumulation of metabolites associated 
with	 IMCL	 (i.e.	 acyl-CoA,	 diacylglycerol	 and	 ceramide)	 is	 a	major	
cause of insulin resistance in skeletal muscle with age (Lee et al., 
2010; Savage et al., 2007).
Despite	 a	 trend	 for	 a	 decrease	 in	 fasting	 blood	 glucose	 in	
Carnitine after 25 weeks, a lack of an effect of increased skeletal 
muscle carnitine content per se on insulin sensitivity was somewhat 
surprising. We have previously demonstrated that a 15% increase in 
skeletal muscle total carnitine, achieved via intravenous L-carnitine 
infusion during a 6 h euglycaemic hyperinsulinaemic clamp in 
healthy young volunteers at rest, increased muscle glycogen content 
by 30% the following morning under controlled dietary conditions 
(Stephens et al., 2006b). Indeed, acute intravenous carnitine admin-
istration in combination with a euglycaemic hyperinsulinaemic clamp 
has been previously demonstrated to improve whole-body glucose 
disposal in normal healthy participants and individuals with type 2 
diabetes	(Capaldo	et	al.,	1991;	De	Gaetano	et	al.,	1999;	Giancaterini	
et al., 2000; Mingrone et al., 1999). Incomplete or insufficient β-ox-
idation of fatty acids, reflected by acylcarnitine accumulation, has 
been implicated in the development of skeletal muscle insulin resis-
tance	(Koves	et	al.,	2008),	and	there	is	growing	interest	in	the	role	
of skeletal muscle carnitine and its associated enzymes in buffering 
these	 negative	 effects.	 For	 example,	 Bruls	 et	 al.,	 (2019)	 observed	
that increasing skeletal muscle carnitine content by 12% in individu-
als	with	impaired	glucose	tolerance	increased	basal	fat	oxidation	by	
around	10%	and	improved	metabolic	flexibility	during	a	mixed	meal	
tolerance	 test.	Although	we	did	 not	 observe	 any	 increase	 in	met-
abolic	 flexibility	during	 the	 insulin	clamp,	nor	an	 increased	muscle	
acetylcarnitine	content	(i.e.	increased	acetyl-CoA	buffering)	during	
exercise	with	elevated	free	carnitine	availability,	we	did	observe	an	
increase	 in	 fat	oxidation	under	basal	 and	 insulin-stimulated	condi-
tions following carnitine loading. This is consistent with the increase 
in	fat	oxidation	during	exercise,	and	was	associated	with	an	increase	
in	gene	expression	of	ACAT1,	the	gene	encoding	acetyl-CoA	acet-
yltransferase	 (also	 known	 as	 acetoacetyl-CoA	 thiolase),	 which	we	
have previously demonstrated to be a main effect of muscle car-
nitine	 loading	 (Stephens	 et	 al.,	 2013).	 Acetoacetyl-CoA	 thiolase	 is	
abundant in skeletal muscle where it functions both in ketogenesis 
and	ketolysis	(from	both	fatty	acids	and	amino	acids),	and	its	maximal	
activity	 has	 been	 demonstrated	 to	 increase	with	 exercise	 training	
(Winder	et	al.,	1975).	We	have	also	previously	shown	that	ACAT1	ex-
pression was reduced in older individuals, which was associated with 






In conclusion, we show for the first time that increasing skeletal 
muscle total carnitine content by 20% in older individuals resulted 
in	an	 increase	 in	whole-body	 total	 fatty	acid	oxidation	at	 rest	and	
during	exercise	at	50%	VO2max.	The	 increase	 in	whole-body	total	
fat	 oxidation	 did	 not	 translate	 into	 reduced	 IMCL	 content,	 an	 im-
proved ability to acetylate-free carnitine or improved insulin sensi-
tivity. It also did not affect body composition, markers of physical 
or mental function, or ability to perform activities of daily living. 
These latter findings should be taken with some caution given the 
low number of participants in the present study and chance of a type 
2 error in some of the variables. However, given that a carnitine-me-
diated	increase	in	mitochondrial	fatty	acid	flux	is	achievable	in	older	
individuals	 during	 moderate-intensity	 exercise	 and	 that	 reduced	
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